Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Oct 11, 2016 10:49am
117 Views
Post# 25330477

Were we "punked" by specific wording in the NR?

Were we "punked" by specific wording in the NR?

Is Spectral choosing to play the "exact words game"?

We know this ended badly for Greg Brady when Mike and Carol let him "play the game".

Note the fact that..."for this sample size" was used twice in the news release..

What about "other sample sizes"?

Interim data suggested 11-12% absolute efficacy.....

The original trial was for 360  patients to show a 15% absolute benefit.

At the interim data point ( 184 patients ), the DSMB/Spectral/FDA all agreed to an adjustment moving the patient count to 650.  The required number was 600, but 650 was the chosen amount to adequately power and complete trial. This trial size suggests expectation / requirement of an eventual 11- 12% absolute efficacy.

We know that 720 patients and the corresponding 10% absolute benefit was set as the minimum level of efficacy for the trial.

How is it that an 11 - 12% absolute benefit demonstrated at the interim data point has been swept under the rug?

Sqr

PS - GO JAYS GO!

Read more at https://www.stockhouse.com/companies/bullboard/t.edt/spectral-medical-inc?postid=25329755#z9eM65vBzqE0zTLg.99
Bullboard Posts